⌘K

Login Start Free

Home/Filings/4/0001209191-20-060665

4//SEC Filing

FEES JESSICA 4

Accession 0001209191-20-060665

CIK 0001718108other

View on SEC.gov Company Profile

Filed

Nov 26, 7:00 PM ET

Accepted

Nov 27, 8:00 PM ET

Size

18.4 KB

Accession

0001209191-20-060665

Insider Transaction Report

Form 4

Period: 2020-11-25

Surface Oncology, Inc.SURF

See Remarks

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2020-11-25−173→ 13,905 total
Exercise: $4.27Exp: 2029-03-01→ Common Stock (173 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2020-11-25−982→ 2,654 total
Exercise: $5.41Exp: 2027-06-27→ Common Stock (982 underlying)
Exercise/Conversion
Common Stock
2020-11-25$5.41/sh+982$5,315→ 102,182 total
Exercise/Conversion
Stock Option (Right to Buy)
2020-11-25−227→ 455 total
Exercise: $4.14Exp: 2026-12-09→ Common Stock (227 underlying)
Exercise/Conversion
Common Stock
2020-11-25$4.27/sh+1$4→ 102,183 total
Exercise/Conversion
Stock Option (Right to Buy)
2020-11-25−1→ 25,999 total
Exercise: $4.27Exp: 2029-03-01→ Common Stock (1 underlying)
Exercise/Conversion
Common Stock
2020-11-25$4.14/sh+227$939→ 101,027 total
Exercise/Conversion
Common Stock
2020-11-25$4.27/sh+173$739→ 101,200 total

Footnotes (4)

[F1]This option shall vest in 48 equal monthly installments after January 1, 2017.
[F2]The stock option vests and becomes exercisable in 48 equal monthly installments after November 18, 2018.
[F3]This option shall vest in 48 equal monthly installments after July 1, 2017.
[F4]The stock option vests and becomes exercisable in 48 equal monthly installments after February 12, 2019.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Surface Oncology, Inc.

CIK 0001718108

Entity typeother

Related Parties

1

filerCIK 0001760391

Filing Metadata

Form type: 4
Filed: Nov 26, 7:00 PM ET
Accepted: Nov 27, 8:00 PM ET
Size: 18.4 KB

View on SEC.gov